These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 29113673)

  • 1. Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.
    Schwameis K; Zehetner J; Hagen JA; Oh DS; Worrell SG; Rona K; Cheng N; Samaan J; Green KM; Lipham JC
    Surg Oncol; 2017 Dec; 26(4):522-526. PubMed ID: 29113673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
    Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
    J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
    Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
    J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy.
    Depypere L; Thomas M; Moons J; Coosemans W; Lerut T; Prenen H; Haustermans K; Van Veer H; Nafteux P
    World J Surg Oncol; 2019 May; 17(1):89. PubMed ID: 31133018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Relevance of Lymph Node Regression After Neoadjuvant Chemoradiation for Esophageal Cancer.
    Philippron A; Bollschweiler E; Kunikata A; Plum P; Schmidt C; Favi F; Drebber U; Hölscher AH
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):549-558. PubMed ID: 28043475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands.
    Visser E; van Rossum PSN; Ruurda JP; van Hillegersberg R
    Ann Surg; 2017 Nov; 266(5):863-869. PubMed ID: 28742691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Pretreatment Pathological Tumor Extent in Patients Treated With Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal or Junctional Cancer.
    Shapiro J; Biermann K; van Klaveren D; Offerhaus GJ; Ten Kate FJ; Meijer SL; van Berge Henegouwen MI; Steyerberg EW; Wijnhoven BP; Lanschot JJ
    Ann Surg; 2017 Feb; 265(2):356-362. PubMed ID: 28059964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
    Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
    Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer.
    Brinkmann S; Noordman BJ; Hölscher AH; Biermann K; van Klaveren D; Bollschweiler E; Pütz K; van Lanschot JJB; Drebber U
    Ann Surg Oncol; 2020 Apr; 27(4):1250-1258. PubMed ID: 31691114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term outcome of neoadjuvant radiochemotherapy followed by surgery for esophageal cancer: a single institution retrospective study of 102 patients].
    Ruffier-Loubière A; Janoray G; Chapet S; de Calan L; Dumont P; Dorval É; Orain I; Calais G
    Cancer Radiother; 2015 Aug; 19(5):322-30. PubMed ID: 26215366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
    Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
    Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.
    Mantziari S; Gronnier C; Renaud F; Duhamel A; Théreaux J; Brigand C; Carrère N; Lefevre JH; Pasquer A; Demartines N; Collet D; Meunier B; Mariette C;
    Ann Surg; 2017 Nov; 266(5):805-813. PubMed ID: 28742698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor differentiation impacts response to neoadjuvant therapy and survival in patients with esophageal adenocarcinoma.
    McKay SC; Louie BE; Molena D; Andrews WG; Boerner T; Hofstetter WL; Yeung J; Darling GE; Sharata A; Peyre CG; Dunn C; Lipham JC; Marginean H; DeMeester SR
    J Thorac Cardiovasc Surg; 2024 Jun; 167(6):1943-1950. PubMed ID: 37788788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant chemoradiation benefit all?
    Hsu PK; Chien LI; Huang CS; Hsieh CC; Wu YC; Hsu WH; Chou TY
    Interact Cardiovasc Thorac Surg; 2013 Sep; 17(3):460-6. PubMed ID: 23728085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma.
    Kawai T; Kochi M; Fujii M; Song K; Hagiwara K; Watanabe M; Matsuno Y; Suda H; Yagi R; Takayama T
    Anticancer Res; 2017 Jun; 37(6):3301-3306. PubMed ID: 28551681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of clinical T2N0M0 esophageal cancer.
    Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
    Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
    Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
    van der Werf LR; Dikken JL; van der Willik EM; van Berge Henegouwen MI; Nieuwenhuijzen GAP; Wijnhoven BPL;
    Eur J Cancer; 2018 Mar; 91():76-85. PubMed ID: 29353163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.